Leo Pharma expands its arsenal of arguments for Adtralza with new long-term data

While Leo Pharma is in full swing with getting eczema treatment Adtralza onto the market, and is anxiously waiting on US approval, the company has presented new long-term data for the drug, causing excitement.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR

Leo Pharma has been developing the medicine tralokinumab for so long that it can now present data for the treament stretching over two years. The drug was already approved earlier this year as a treatment for atopic dermatitis in the EU under the name Adtralza.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading